Zantac (Ranitidine) Lawsuit
NDMA Cancer Claims
One of the largest pharmaceutical MDLs with over 15,000 total actions filed. Plaintiffs alleged that the heartburn medication Zantac contained the carcinogen NDMA, but a landmark Daubert ruling in December 2022 excluded nearly all plaintiff expert testimony, fundamentally reshaping the litigation.
Key Takeaways
- 15,016 total actions filed — one of the largest pharmaceutical MDLs, with only ~851 pending as of May 2026
- FDA withdrew all ranitidine products from U.S. market on April 1, 2020, citing NDMA instability at elevated temperatures
- Judge Rosenberg's 300+ page Daubert ruling (December 2022) excluded all plaintiff causation experts, effectively blocking litigation path forward
- Delaware Supreme Court reversed lower court in July 2025 (342 A.3d 1131), but federal Daubert ruling remains binding
- No global settlement — recruitment officially closed; litigation winding down after expert exclusions
May 2026 Updates Latest
847 pending actions out of 60,735 total filed per the May 2026 JPML statistics report. Plaintiffs are still awaiting an Eleventh Circuit ruling nearly seven months after October 10, 2025 oral arguments before the three-judge panel challenging Judge Rosenberg's 341-page December 2022 Daubert order, which excluded all ten plaintiffs' general-causation experts and effectively dismissed roughly 50,000 federal claims — a reversal would revive the MDL and reopen the door to thousands of ranitidine cancer claims.
State courts remain the active battleground in Delaware, California, and Illinois. Following the Delaware Supreme Court's July 2025 reversal of the trial court's Daubert order, Superior Court Judge Vivian Medinilla is conducting renewed expert-testimony evaluation under the corrected standard. GSK's previously reported $2.2 billion settlement framework covering roughly 80,000 state-court claims continues rolling out, while Boehringer Ingelheim — with seven Cook County defense verdicts and a recent eighth win — is gearing up for Connecticut bellwether trials scheduled for March 2028.
Key Facts (May 2026)
| Pending Actions | 847+ cases in federal MDL |
| Total Actions Filed | 15,018+ total actions filed |
| Resolution Rate | 94% resolved or dismissed |
| Key Defendants | GlaxoSmithKline, Sanofi, Boehringer Ingelheim, Pfizer |
| Presiding Judge | Hon. Robin L. Rosenberg (S.D. Florida) |
| MDL Created | February 2, 2020 (transferred by JPML) |
| Drug Contaminant | NDMA (N-Nitrosodimethylamine, Group 2A carcinogen) |
| FDA Action | Market withdrawal of all ranitidine products (April 1, 2020) |
| Landmark Ruling | Daubert order (Dec 2022): excluded all causation experts |
| Can You Still File? | Recruitment closed; litigation winding down |
FDA Market Withdrawal (April 1, 2020)
The FDA requested that all manufacturers withdraw ranitidine (brand name Zantac and generics) from the U.S. market due to unacceptable levels of the probable human carcinogen NDMA. The agency stated that NDMA levels in ranitidine products increase over time, especially at elevated temperatures.
"The FDA is requesting that all ranitidine products be removed from the market immediately."
— FDA Statement, April 1, 2020
Ranitidine remains unavailable in the United States. In Australia, generic ranitidine was reapproved in 2024 with specific storage requirements.
Case Trajectory
Zantac MDL filings surged to 14,401 pending cases by mid-2024 before mass settlements by Pfizer (~10,000 cases) and Sanofi (~4,000 cases) dramatically reduced the pending count. Only 847 cases remain pending.
Source: JPML MDL Statistics Reports, February 2020–May 2026
1 What Is This Lawsuit About?
MDL-2924 is one of the largest pharmaceutical multidistrict litigations with 15,016 total actions filed. Plaintiffs alleged that ranitidine (Zantac), a widely-used heartburn and acid reflux medication, contained and generated the carcinogen NDMA (N-nitrosodimethylamine) during storage and use, which caused various cancers.
The lawsuits were filed against brand manufacturers (GlaxoSmithKline, Sanofi, Boehringer Ingelheim, Pfizer) and generic manufacturers. However, the litigation's trajectory was fundamentally altered by a landmark Daubert ruling in December 2022 that excluded all plaintiff expert testimony on whether ranitidine can cause cancer.
2 What Is Zantac (Ranitidine)?
Ranitidine is a histamine H2 receptor antagonist approved by the FDA in 1983 for prescription use and 1995 for over-the-counter use. It works by reducing stomach acid production, making it effective for heartburn, acid reflux (GERD), and ulcers.
Under the brand name Zantac, it became the world's largest-selling prescription medication by 1987. By 2018, approximately 19 million ranitidine prescriptions were filled annually in the United States. The drug was manufactured and sold by GlaxoSmithKline (original developer), Sanofi, Boehringer Ingelheim, and Pfizer.
Conditions Treated by Ranitidine
Timeline of Ranitidine Approvals
3 NDMA Discovery & FDA Withdrawal
NDMA (N-nitrosodimethylamine) is classified by the International Agency for Research on Cancer (IARC) as a Group 2A probable human carcinogen. The FDA has established a 96 nanogram per day acceptable intake limit for NDMA in medications.
In September 2019, the online pharmacy testing service Valisure published research indicating that ranitidine products contained NDMA at levels exceeding FDA limits. Valisure's testing involved heating ranitidine tablets to 50°C (122°F) and 77°C (170°F) to simulate storage conditions—discovering NDMA levels reaching 266 nanograms, nearly 3x the FDA acceptable intake.
The Valisure Controversy
Valisure's testing methodology became central to litigation discovery. The company heated tablets to temperatures that may exceed real-world conditions, raising questions about whether NDMA formation in patient medicine cabinets actually occurred.
The FDA subsequently conducted its own testing and in December 2019 confirmed that ranitidine generates NDMA when exposed to higher temperatures and in the presence of sodium nitrite. The agency also noted that NDMA levels in finished ranitidine products increase over time.
FDA Timeline
Online pharmacy testing service reports NDMA in ranitidine products exceeding FDA acceptable intake levels.
FDA states it is investigating NDMA in ranitidine products. Initial holds and recalls begin.
FDA announces that ranitidine generates NDMA, particularly at elevated temperatures and when exposed to sodium nitrite.
FDA requests that all manufacturers withdraw all ranitidine products from the U.S. market due to unacceptable NDMA levels.
4 The Scientific Debate
Plaintiffs alleged that ranitidine use caused multiple types of cancer. However, the scientific evidence has been contested throughout the litigation.
Cancers Alleged in Litigation
Evidence Supporting Link
- • NDMA is IARC Group 2A probable carcinogen
- • Ranitidine generates NDMA at elevated temperatures (FDA confirmed)
- • NDMA levels in products increase over time
- • Stomach cancer epidemiologically linked to NDMA exposure in rodent studies
- • Ranitidine use widespread (millions of prescriptions annually)
Challenges to Causation
- • No human epidemiological studies showing ranitidine/cancer link
- • Valisure testing heated tablets to non-physiologic temperatures
- • FDA clinical trials found no NDMA in patient bodies
- • Stanford study later retracted concerning NDMA body levels
- • Daubert gate-keeping excluded plaintiff causation experts
5 The Landmark Daubert Ruling
Rosenberg v. Zantac Litigation
644 F. Supp. 3d 1075 (S.D. Fla. 2022)
December 28, 2022 — Judge Robin L. Rosenberg issued a 300+ page Daubert opinion excluding all plaintiff expert witnesses on general causation (whether ranitidine can cause cancer at all).
A Daubert hearing is a gatekeeping procedure under Federal Rule of Evidence 702, where a judge must determine whether expert testimony is reliable before allowing it at trial. The expert's opinion must be based on sufficient facts or data, reliably applied reliable principles and methods, and the application of these principles must result in reliable conclusions.
Impact: Expert exclusion meant plaintiffs could not present expert testimony that ranitidine caused cancer, effectively removing the scientific foundation of the litigation. Approximately 14,000+ cases were dismissed following this ruling. The Eleventh Circuit Court of Appeals apparently affirmed the Daubert order (date and docket pending).
6 State Court Proceedings
While federal MDL proceedings have been constrained by the Daubert ruling, parallel state court litigations have proceeded with different outcomes.
Delaware
Delaware state court initially allowed plaintiff expert testimony on causation in a consolidated case involving approximately 75,000 plaintiffs.
July 2025 Development: Delaware Supreme Court reversed the lower court decision in 342 A.3d 1131, aligning more closely with the Daubert-style exclusion approach. However, the reversal was limited in scope and state-specific.
Status: Proceedings continue; federal Daubert ruling's precedential effect on federal and many state courts remains significant.
Illinois
Illinois state court proceedings have advanced more quickly, with several cases reaching verdict.
Valadez v. GSK (2023): Cook County jury returned a defense verdict after finding insufficient evidence that ranitidine caused plaintiff's cancer. Verdict affirmed on appeal.
Status: Other Illinois cases are proceeding, but the defense verdict suggests plaintiff burden of proof is challenging even in state court.
7 Settlement Status & Current Status
No global settlement has been reached in MDL-2924. The Daubert ruling in December 2022 fundamentally changed settlement incentives. With expert testimony excluded, defendants have less motivation to settle, and plaintiff attorneys face significantly reduced case values.
Most law firms specializing in mass tort litigation ceased active recruitment for Zantac cases in 2023 following the expert exclusion order. Settlement activity has slowed considerably compared to the initial filing surge in 2020-2021.
Pending Case Status (March 2026)
The litigation is effectively winding down. No further major settlements or trial activity is anticipated unless there is a significant appellate reversal of the Daubert ruling.
8 Key Defendants
Brand Manufacturers
- GlaxoSmithKline (GSK)
Original developer and manufacturer of Zantac; sold brand to Boehringer Ingelheim in 2006.
- Boehringer Ingelheim
Acquired Zantac brand from GSK; primary defendant during most relevant period.
- Sanofi
Manufacturer of generic ranitidine; named defendant in litigation.
- Pfizer
Also named as defendant; manufactured ranitidine products.
Also Named in Litigation
- Patheon Inc.
Contract manufacturer; supplied ranitidine products.
- Generic Manufacturers
Amneal, Amphastar, Eugia Pharma, Xiromed, and others.
- Retailers
Walgreens, CVS, and other pharmacy chains sold ranitidine OTC.
- Online Pharmacies
Amazon Pharmacy and other e-commerce sellers.
Frequently Asked Questions
Did the FDA say ranitidine causes cancer?
No. The FDA has not concluded that ranitidine causes cancer in humans. The agency withdrew the product based on the presence of NDMA and NDMA's classification as a probable carcinogen. This was a precautionary action, not a determination of actual human harm.
What is NDMA exactly?
NDMA (N-nitrosodimethylamine) is classified as a Group 2A probable human carcinogen by IARC. It has been shown to cause cancer in laboratory animals. The FDA limits acceptable NDMA daily intake in medications to 96 nanograms per day. NDMA can form in ranitidine tablets when exposed to elevated temperatures.
Can I still file a Zantac lawsuit?
Recruitment is closed. Most law firms are no longer actively accepting new Zantac cases. The Daubert expert exclusion order makes litigation very difficult. If you have a potential claim, contact an attorney immediately, as statute of limitations varies by state (typically 2-4 years from diagnosis).
What happened in the Delaware Supreme Court case?
In July 2025, the Delaware Supreme Court reversed a lower court decision that had allowed plaintiff expert testimony. The decision (342 A.3d 1131) moved Delaware more in line with federal Daubert-style gatekeeping, though it was state-specific and limited in scope.
What was the Daubert ruling exactly?
December 28, 2022: Judge Rosenberg issued a 300+ page order (644 F. Supp. 3d 1075) excluding all plaintiff expert witnesses on general causation—the question of whether ranitidine can cause cancer. Without expert testimony on this foundational issue, plaintiffs cannot proceed to trial, leading to dismissal of thousands of cases.
Is ranitidine still available?
Ranitidine is not available in the United States following the FDA withdrawal on April 1, 2020. Generic ranitidine was reapproved in Australia in 2024 with specific storage requirements. Other H2 blockers like famotidine (Pepcid) are available as alternatives.
What cancers are alleged in the lawsuits?
Plaintiffs alleged bladder, stomach, liver, esophageal, pancreatic, colorectal, and kidney cancers. However, the Daubert ruling excluded expert testimony linking ranitidine to these cancers, making litigation difficult without scientific proof.
Are there any settlements?
No global settlement has been reached. Individual settlements occur occasionally, but the Daubert ruling eliminated the incentive for broad settlements. Defendants have limited motivation to settle when expert causation testimony is excluded.
Sources & References
15 official sources cited• Rosenberg v. Zantac Litigation, 644 F. Supp. 3d 1075 (S.D. Fla. 2022) — Daubert ruling
• FDA Statement on Ranitidine Market Withdrawal, April 1, 2020
• FDA Docket ID FDA-2019-N-4640 (Ranitidine investigation)
• Valisure Petition to FDA Regarding Ranitidine NDMA Content, September 2019
• International Agency for Research on Cancer (IARC) Monograph on NDMA (Group 2A)
• FDA Acceptable Daily Intake for NDMA: 96 nanograms per day
• Delaware Supreme Court Decision, 342 A.3d 1131 (July 2025)
• JPML MDL-2924 Official Docket and Case Management Orders
• U.S. District Court, Southern District of Florida — MDL-2924 Case Documents
• AboutLawsuits.com, "Zantac Lawsuit News and Updates," February 2026
• Valadez v. GlaxoSmithKline Cook County verdict (2023)
• FDA Prescribing Information for Ranitidine Products (prior to withdrawal)
• Eleventh Circuit Court of Appeals docket (Daubert appeal status)
• American Cancer Society, "Understanding Cancer Types Alleged in Zantac Litigation"
• Judicial Panel on Multidistrict Litigation (JPML) MDL Transfer Order, February 2, 2020
Attorney Advertising. The information on this page is provided for general informational purposes only and does not constitute legal advice. No attorney-client relationship is created by accessing or using this content.
Every case is unique, and results depend on the specific facts and circumstances involved. Past settlement amounts and case outcomes do not guarantee similar results in your case. If you believe you have a legal claim, you should consult with a licensed attorney in your jurisdiction who can evaluate your specific situation.